Eqis Capital Management, Inc. Jounce Therapeutics, Inc. Transaction History

Eqis Capital Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $300,253 - $426,649	-49,959 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $137,365 - $186,244	19,320 Added 63.06%	49,959 $417,000
Q3 2021 Nov 12, 2021	BUY	$5.04 - $8.73 $7,156 - $12,396	1,420 Added 4.86%	30,639 $228,000
Q2 2021 Aug 12, 2021	BUY	$6.58 - $10.66 $71,064 - $115,128	10,800 Added 58.64%	29,219 $199,000
Q1 2021 May 14, 2021	BUY	$6.73 - $13.87 $123,959 - $255,471	18,419 New	18,419 $189,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.